Dermatology

Top Medical News
Laser superior to cryotherapy for hard-to-treat warts
2 hours ago
Use of long-pulsed neodymium-doped yttrium-aluminium-garnet (LP-Nd:YAG) laser provides similar overall therapeutic effects to those of cryotherapy, results of a recent study have shown. However, laser appears more effective against recalcitrant warts and results in shorter time to warts clearance.
Itraconazole effective for ringworm of the body but requires longer treatment
7 hours ago
Itraconazole appears to be effective in the treatment of patients with tinea corporis/cruris (TCC) or ringworm of the body, as shown in a study. However, the treatment duration needs to be longer and, even with successful treatment, many patients experience relapse.
Original New Drug Application Approvals by US FDA (16 - 30 November 2022)
Yesterday
New drug applications approved by US FDA as of 16 - 30 November 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Pembrolizumab extends RFS in stage II melanoma
3 days ago
There appears to be low to no metastatic potential for melanocytic tumours of uncertain malignant potential (MELTUMP) and superficial atypical melanocytic proliferations of uncertain significance (SAMPUS), a recent study has found.
Inflammatory bowel disease may cause psoriasis, psoriatic arthritis
22 Nov 2022
Inflammatory bowel disease appears to be a causal risk factor for both psoriasis and psoriatic arthritis, with Crohn’s disease specifically associated with the development of the two psoriasis outcomes, according to a study.
COVID-19 may trigger hair, nail disorders
21 Nov 2022
Hair and nail disorders may occur following contraction of COVID-19 infection, with the development of the dermatological conditions related to a history of severe infection, a study has found.
Oral ritlecitinib shows promise against nonsegmental vitiligo
17 Nov 2022
The use of ritlecitinib, an oral JAK3/TEC inhibitor, appears effective for the treatment of nonsegmental vitiligo (NSV) and is well-tolerated for over 48 weeks of follow-up, reports a recent study.
Special Reports
Product Highlight - Canespro
15 Jun 2022
Bifonazole Anti-Fungal Cream 1% w/w
Product Highlight - RELIZEMA
16 Jun 2021
Furfuryl Palmitate
Expert consensus: Patient profile should guide antihistamine choice in primary care setting
10 Dec 2019
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Antihistamine therapy for allergic rhinitis and urticaria: An Asia-Pacific perspective
01 Nov 2018
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
Improving Medical Practice through Advancement in Clinical Treatment: IMPACT Aesthetics & Suturing Workshop 2018
Dr. Steven Ang, Dr. Leo Kah Woon, 11 Jul 2018
DCH Auriga recently held their first Aesthetics and Suturing Workshop under the IMPACT continuing medical education series – a scientific platform that aims to cascade the latest updates on disease management and share best clinical practices among healthcare professionals in Singapore. Two experts on aesthetics and aesthetic surgery shared their insights on suturing techniques and current approaches for scar prevention and management.
Cochrane review confirms Atopiclair efficacy in eczema
22 Dec 2017
Eczema (atopic dermatitis) is a chronic inflammatory skin disease that can present in many different forms. However, it is principally characterized by dry skin, intense itching, and the presence of inflammatory skin lesions. [J Eur Acad Dermatol Venereol 2016;30:604-618; N Engl J Med 2008;358:1483-1494; Lancet 2016;387:1109-1122]
Conference Reports
Skin biomarkers predict AD risk, severity in newborns
Elvira Manzano, 27 Oct 2022
Predicting which newborn will go on to develop atopic dermatitis (AD) and how severe it will be is now feasible, according to the BABY* study.
Ruxolitinib improves repigmentation in vitiligo through 52 weeks
Elaine Soliven, 21 Oct 2022
Long-term use of ruxolitinib cream continued to improve facial and total body repigmentation in patients with nonsegmental vitiligo from 24 to 52 weeks, according to an updated pooled analysis of the phase III TRuE-V1* and TRuE-V2** studies presented at EADV 2022.
Dupilumab reduces itch, improves skin lesions in prurigo nodularis
Elvira Manzano, 20 Oct 2022
Dupilumab improves itch response and skin lesions in patients with prurigo nodularis (PN) inadequately controlled with prior therapies in the LIBERTY-PN PRIME trial.
Lebrikizumab efficacy in atopic dermatitis maintained at 1 year
Roshini Claire Anthony, 12 Oct 2022

Maintenance lebrikizumab monotherapy appears to improve outcomes in patients with moderate-to-severe atopic dermatitis (AD), according to results of the phase III ADvocate1 and ADvocate2 trials.

Ligelizumab safe, effective in patients with chronic spontaneous urticaria
Elaine Soliven, 06 Oct 2022
Ligelizumab, a next-generation anti-IgE antibody, is safe and effective in treating patients with H1-antihistamine (H1-AH) refractory chronic spontaneous urticaria (CSU), according to two phase III studies presented at EADV 2022.
Deucravacitinib bestows benefits in Asian patients with plaque psoriasis
Roshini Claire Anthony, 04 Oct 2022

The benefit of deucravacitinib in moderate to severe plaque psoriasis was demonstrated in a population of Asian patients, according to results of the phase III POETYK PSO-3 trial.

Rocatinlimab a new treatment option for head and neck AD?
Audrey Abella, 23 Sep 2022
Rocatinlimab improved disease severity in patients with moderate-to-severe head and neck atopic dermatitis (H&N AD), a post hoc analysis of a phase IIb trial has shown.
Product Highlights
CME Modules